Let-7b in BPD
Let-7b in BPD
批准号:
10655734
负责人:
Namasivayam Ambalavanan
金额:
$55.44万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-14 至 2027-03-31
关键词:
AdultAgeAlveolarAngiogenesis InhibitionAttenuatedBasic ScienceBiological MarkersBirthBloodBlood VesselsBronchopulmonary DysplasiaCell Culture SystemCell Culture TechniquesCessation of lifeClinicalDevelopmentDisease ProgressionEarly identificationEpithelial CellsExtremely Low Birth Weight InfantFetal LungFunctional disorderGenomicsHumanHyperoxiaImpairmentIncidenceInfantLungLung diseasesMeasuresMechanicsMediatorMessenger RNAMetagenomicsMicroRNAsMitochondriaModelingMonitorMorbidity - disease rateMusNF-kappa BNewborn InfantOxidative StressOxygenPhenotypePlasmaPremature InfantProspective cohortProteomicsPulmonary FibrosisPulmonary HypertensionResearchRiskRoleSamplingSeverity of illnessSignal TransductionSmall RNASourceStagingStructure of parenchyma of lungTestingTimeTracheaTransgenic MiceUrineVascular remodelingairway epitheliumangiogenesisaspiratebiomarker identificationcohortcytokineexome sequencingextreme prematuritygenome wide association studyimprovedinhibitorlung developmentmetabolomicsmicrobialmicrobiomemicrobiome researchmouse modelnormoxianovelnovel therapeutic interventionoverexpressionpostnatalprospectivepulmonary functionrespiratorytranscriptome sequencingtranscriptomicstreatment response
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Bronchopulmonary dysplasia (BPD) is common in extremely low birth weight (ELBW) infants.
Recently, we discovered that the strongest biomarker signal was of microRNA let-7b-5p, with a 46-fold
increase (p<0.001) at birth in the blood of infants who subsequently developed severe BPD (versus
no BPD) many weeks later at 36w post-menstrual age. We also found a 14-fold increase of let-7b-5p on day
1 in the tracheal aspirate of infants who subsequently developed BPD. In cell culture, airway epithelial cells
were the primary source of let-7b-5p, that increased with hyperoxia. We found that excessive let-7b inhibits
angiogenesis, and that let-7b inhibition during hyperoxia improves lung development in newborn mice.
In the “Let-7b in BPD” project, we will build upon our exciting discovery of let-7b-5p as a robust
biomarker of BPD, and determine its relevance to lung development and BPD. We will test the central
hypotheses that miRNA let-7b-5p is (a) a valuable biomarker for staging, monitoring disease
progression and response to therapy, (b) is released from airway epithelial cells by oxidative stress,
(c) is a contributor to dysregulated angiogenesis in bronchopulmonary dysplasia, and (d) that
inhibition of let-7b signaling improves lung angiogenesis and attenuates the BPD phenotype.
We will test the hypotheses by the following Specific Aims:
Specific Aim 1 – Determine if plasma let-7b-5p concentrations in extremely preterm infants track with lung
disease progression and correlate with response to therapy.
Let-7b-5p will be measured in serial plasma samples from a well characterized prospective cohort of
150 extremely preterm infants. We will define the temporal changes in let-7b-5p with respiratory illness
severity, BPD staging and lung mechanics at 36w PMA, and with clinical therapies.
Specific Aim 2 – Determine the mechanisms of Let-7b release by newborn mouse lung airway epithelium
To confirm that the let-7b-5p release by oxidative stress is the key upstream mechanism, we will use
novel transgenic mice. We will test the hypothesis that reduction of mitochondrial ROS reduces let-7b-5p
and the BPD phenotype, and determine the role of Nrf2 and NF-kB signaling using specific
inhibitors/modulators in cell culture models.
Specific Aim 3 – Determine effects of excessive let-7b-5p signaling on lung microvascular development.
We will test the hypothesis that over-expression of let-7b-5p induces impaired lung microvascular
development, inducing a BPD phenotype in newborn mice even in normoxia, and that inhibition of let-7b-5p
improves lung development in hyperoxia- exposed newborn mouse lung (BPD model).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.
-
批准号:10576754
-
项目类别:
-
资助金额:$50.02万
-
财政年份:2023
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Vital Signs In Opioid-Exposed Neonates
-
批准号:10493363
-
项目类别:
-
资助金额:$50.77万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments
-
批准号:10891299
-
项目类别:
-
资助金额:$22.15万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age
-
批准号:10363406
-
项目类别:
-
资助金额:$148.56万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments
-
批准号:10372486
-
项目类别:
-
资助金额:$44.29万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Vital Signs In Opioid-Exposed Neonates
-
批准号:10360908
-
项目类别:
-
资助金额:$51.99万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age
-
批准号:10541156
-
项目类别:
-
资助金额:$152.13万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Acute Renal Injury Sequelae in NICU Graduates (ARISING)
-
批准号:9899244
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2019
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:10006023
-
项目类别:
-
资助金额:$53.71万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:9762173
-
项目类别:
-
资助金额:$56.38万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:9168075
-
项目类别:
-
资助金额:$19.53万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:9292368
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:9143795
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:8996355
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:9062496
-
项目类别:
-
资助金额:$73.48万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:8685690
-
项目类别:
-
资助金额:$74.01万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:8870421
-
项目类别:
-
资助金额:$73.5万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8240026
-
项目类别:
-
资助金额:$59.75万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8610334
-
项目类别:
-
资助金额:$57.19万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8015539
-
项目类别:
-
资助金额:$62.29万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: